A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

In this study, we delved into the safety profile of alpelisib, an FDA-approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, and PIK3CA-Related Overgrowth Spectrum (PROS). Despite its approval, real-world, long-term safety data is lackin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yu Lin, Xinlei Zheng, Yan Chen, Qichun Nian, Li Lin, Maohua Chen
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-03-01
Col·lecció:	Heliyon
Matèries:	Alpelisib Adverse event FAERS database Disproportionality analysis Pharmacovigilance
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2405844024035606
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!